TY - JOUR
T1 - Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin
AU - Healy, David
AU - Bahrick, Audrey
AU - Bak, Maarten
AU - Barbato, Angelo
AU - Calabrò, Rocco Salvatore
AU - Chubak, Barbara M
AU - Cosci, Fiammetta
AU - Csoka, Antonei B
AU - D'Avanzo, Barbara
AU - Diviccaro, Silvia
AU - Giatti, Silvia
AU - Goldstein, Irwin
AU - Graf, Heiko
AU - Hellstrom, Wayne J G
AU - Irwig, Michael S
AU - Jannini, Emmanuele A
AU - Janssen, Paddy K C
AU - Khera, Mohit
AU - Kumar, Manoj Therayil
AU - Le Noury, Joanna
AU - Lew-Starowicz, Michał
AU - Linden, David E J
AU - Lüning, Celine
AU - Mangin, Dee
AU - Melcangi, Roberto Cosimo
AU - Rodríguez, Omar Walid Muquebil Ali Al Shaban
AU - Panicker, Jalesh N
AU - Patacchini, Arianna
AU - Pearlman, Amy M
AU - Pukall, Caroline F
AU - Raj, Sanjana
AU - Reisman, Yacov
AU - Rubin, Rachel S
AU - Schreiber, Rudy
AU - Shipko, Stuart
AU - Vašečková, Barbora
AU - Waraich, Ahad
N1 - Funding Information:
Emmanuele A. Jannini is supported in part by the Italian Ministry of University and Research Grant PRIN #2017S9KTNE_002. Dee Mangin is supported by the David Braley Chair in Family Medicine, McMaster University. Jalesh N. Panicker is supported in part by funding from the United Kingdom’s Department of Health NIHR Biomedical Research Centres.
Publisher Copyright:
© 2022 - The authors. Published by IOS Press.
PY - 2022/2/22
Y1 - 2022/2/22
N2 - BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin.OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD).METHODS: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts.RESULTS: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor.CONCLUSIONS: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.
AB - BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin.OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD).METHODS: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts.RESULTS: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor.CONCLUSIONS: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.
KW - Post-SSRI sexual dysfunction
KW - antidepressants
KW - selective serotonin reuptake inhibitors
KW - finasteride
KW - isotretinoin
KW - GENITAL AROUSAL DISORDER
KW - PREMATURE EJACULATION
KW - DOUBLE-BLIND
KW - PERSISTENT
KW - CITALOPRAM
KW - EFFICACY
KW - SAFETY
U2 - 10.3233/JRS-210023
DO - 10.3233/JRS-210023
M3 - Article
C2 - 34719438
SN - 0924-6479
VL - 33
SP - 65
EP - 76
JO - International Journal of Risk and Safety in Medicine
JF - International Journal of Risk and Safety in Medicine
IS - 1
ER -